Korean J Intern Med.
2017 Mar;32(2):335-344. 10.3904/kjim.2015.161.
Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
- Affiliations
-
- 1Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. drosy@dau.ac.kr
- 2Immune-Network Pioneer Research Center, Dong-A University College of Medicine, Busan, Korea.
- 3Department of Biochemistry, Dong-A University College of Medicine, Busan, Korea.
- 4Department of Pathology, Dong-A University College of Medicine, Busan, Korea.
- KMID: 2371657
- DOI: http://doi.org/10.3904/kjim.2015.161
Abstract
- BACKGROUND/AIMS
CD11c is a dendritic cell marker in humans, which potentially induces a cytotoxic effect on lymphoma cells. Forkhead boxP3 (FOXP3) is a regulator of T lymphocyte in the microenvironment of the lymphoma. The principal objective of this study was to determine whether the tumors' microenvironment expressions of CD11c and FOXP3 are predictive of clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients receiving treatment with rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
METHODS
The study population consisted of 100 patients with DLBCL. The CD11c and FOXP3 expression in primary tumors' microenvironment were evaluated using an immunohistochemistry (IHC).
RESULTS
CD11c and FOXP3 expression positivity in microenvironment were 25% and 35%, respectively. Each one counted for 1 point. In CD11c and FOXP3 stain, positive was counted as 0 and negative was 1. The points were separated into low risk (0 to 1) and high risk (2) groups. Only the extranodal DLBCL patient group analysis conveyed significant differences of progression-free survival (p = 0.019) and overall survival (p = 0.039) between the two groups.
CONCLUSIONS
We can achieve possible clinical significance of lymphoma tumor microenvironments through CD11c and FOXP3 IHC stains in extranodal DLBCL patients receiving R-CHOP therapy.
MeSH Terms
-
B-Lymphocytes*
Coloring Agents
Cyclophosphamide*
Dendritic Cells
Disease-Free Survival
Drug Therapy, Combination*
Humans
Immunohistochemistry
Lymphocytes
Lymphoma
Lymphoma, B-Cell*
Lymphoma, Large B-Cell, Diffuse
Prednisone*
Rituximab*
Tumor Microenvironment*
Vincristine*
Coloring Agents
Cyclophosphamide
Prednisone
Rituximab
Vincristine
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
- Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
- A Case of Primary Thyroid Lymphoma Originated from Thyroid Gland
- A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy
